A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

BI 10773

BI 10773 tablets once daily high dose

Trial Locations (3)

1245.39.43001 Boehringer Ingelheim Investigational Site, Graz

1245.39.49002 Boehringer Ingelheim Investigational Site, Neuss

1245.39.39001 Boehringer Ingelheim Investigational Site, Pisa